Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.
Trade-Ideas LLC identified Theravance (THRX) as a "dead cat bounce" (down big yesterday but up big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified Theravance as such a stock due to the following factors:
- THRX has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $18.8 million.
- THRX has traded 385,109 shares today.
- THRX is up 4.6% today.
- THRX was down 19.4% yesterday not including the $5.60 cash equivalent distribution in the form of a spin-off stock of Theravance Biopharma (TBPH). Including the spin-off the shares rose 0.2%.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in THRX with the Ticky from Trade-Ideas. See the FREE profile for THRX NOW at Trade-Ideas
More details on THRX:
Theravance, Inc., a biopharmaceutical company, is engaged in the discovery, development, and commercialization of small molecule medicines primarily for therapeutic areas of respiratory diseases, bacterial infections, and central nervous system/pain. Currently there are 4 analysts that rate Theravance a buy, 1 analyst rates it a sell, and 1 rates it a hold.
The average volume for Theravance has been 988,100 shares per day over the past 30 days. Theravance has a market cap of $3.2 billion and is part of the health care sector and drugs industry. The stock has a beta of 0.63 and a short float of 44% with 25.72 days to cover.